MedTrace Logo

Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

NCT03025945 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 662

Last updated 2018-12-14

Study results available
· View outcomes & findings →

Summary

Prospective, randomized, double-masked, placebo-controlled clinical study to define the effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema.

Conditions

  • Cystoid Macular Edema

Interventions

DRUG

Nepafenac 0.3%

DRUG

Saline Solution

Sponsors & Collaborators

  • Intuor Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Sean McCafferty, MD · Arizona Eye Consultants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2017-01-31
Completion
2017-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03025945 on ClinicalTrials.gov